Marshall Wace, LLP 2seventy Bio, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 275,536 shares of TSVT stock, worth $727,415. This represents 0.0% of its overall portfolio holdings.
Number of Shares
275,536
Previous 468,883
41.24%
Holding current value
$727,415
Previous $2.21 Million
63.4%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TSVT
# of Institutions
127Shares Held
44.8MCall Options Held
17.3KPut Options Held
2.9K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$15.7 Million1.11% of portfolio
-
Goldman Sachs Group Inc New York, NY4.29MShares$11.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$9.93 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$9.67 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.92MShares$7.7 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $100M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...